Moleculin Biotech, Inc.
NASDAQ: MBRX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Walter V. Klemp
- Employees
- 17
- Headquarters
- Houston, United States
- IPO year
- 2016
- Market cap
- $15.6M
- Website
- https://www.moleculin.com
Loading MBRX…
Loading profile data…Frequently asked questions about MBRX
What does Moleculin Biotech, Inc. (MBRX) do?
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemi...
Where does MBRX trade?
Moleculin Biotech, Inc. (MBRX) trades on the NASDAQ Capital Market.
What sector is MBRX in?
Moleculin Biotech, Inc. (MBRX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Moleculin Biotech, Inc.?
Walter V. Klemp is the chief executive officer of Moleculin Biotech, Inc. (MBRX).
Where is Moleculin Biotech, Inc. headquartered?
Moleculin Biotech, Inc. is headquartered in United States.
Does MBRX pay a dividend?
Moleculin Biotech, Inc. (MBRX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MBRX go public?
Moleculin Biotech, Inc. (MBRX) completed its initial public offering in 2016.